Asunto(s)
Anticonvulsivantes/metabolismo , Piracetam/análogos & derivados , Complicaciones del Embarazo/tratamiento farmacológico , Convulsiones/tratamiento farmacológico , Anticonvulsivantes/uso terapéutico , Femenino , Humanos , Levetiracetam , Piracetam/metabolismo , Piracetam/uso terapéutico , EmbarazoRESUMEN
BACKGROUND: Use of valproate in pregnancy, especially in doses over 1000mg a day, is known to be associated with a higher risk for major congenital malformations compared with other antiepileptic drugs. We sought to investigate whether the increased risk could be minimised by using controlled release or divided daily doses of valproate. METHODS: The UK Epilepsy and Pregnancy Register is a prospective, observational and follow up study set up to determine the risks of major congenital malformations for infants exposed to antiepileptic drugs in utero. In this study we have extracted data for those pregnancies exposed to valproate in monotherapy. We have calculated malformation rates and relative risks as a function of valproate exposure. RESULTS: Outcome data were available for 1109 pregnancies exposed to valproate in monotherapy. Exposure to 1000mg a day or more of valproate was associated with almost double the risk of major congenital malformation compared with daily valproate doses below 1000mg daily (8.86% vs 4.88%, RR: 1.7; 95% CI: 1.1-2.9). There were no differences in the risks for malformations between standard release valproate and controlled release valproate preparations (RR: 1.11; 95% CI: 0.67-1.83) or for those exposed to single or multiple daily administrations (RR: 0.99, 95% CI: 0.58-1.70). CONCLUSION: Prescribing controlled release valproate or multiple daily administrations in pregnancy did not reduce the risk for malformations. Higher malformation rates observed with in utero exposure to valproate are more likely related to total daily dose, rather than peak serum levels.
Asunto(s)
Anomalías Inducidas por Medicamentos/epidemiología , Anticonvulsivantes/efectos adversos , Epilepsia/tratamiento farmacológico , Complicaciones del Embarazo/tratamiento farmacológico , Ácido Valproico/efectos adversos , Anticonvulsivantes/administración & dosificación , Femenino , Humanos , Embarazo , Efectos Tardíos de la Exposición Prenatal/epidemiología , Factores de Riesgo , Ácido Valproico/administración & dosificaciónRESUMEN
An elderly female smoker presented with nausea and anorexia. Imaging and histopathology were consistent with a diagnosis of small cell lung cancer (SCLC). She subsequently developed a progressive sensorimotor neuropathy with high titres of anti-Hu antibodies. Development of the neuropathy was associated with marked regression in the lung neoplasm. Repeat investigation with radioimaging and bronchoscopy showed no evidence of neoplasia. Paraneoplastic sensorimotor neuropathies are commonly associated with SCLC particularly in the presence of anti-Hu antibodies. Regression of SCLC with anti-Hu antibodies has only been reported twice previously. The authors believe this case supports the theory that anti-Hu antibodies confer anti-tumour activity causing tumour regression.
Asunto(s)
Autoanticuerpos/sangre , Proteínas ELAV/inmunología , Neoplasias Pulmonares/inmunología , Regresión Neoplásica Espontánea/inmunología , Síndromes Paraneoplásicos del Sistema Nervioso/diagnóstico , Carcinoma Pulmonar de Células Pequeñas/inmunología , Anciano , Biomarcadores/sangre , Resultado Fatal , Femenino , Humanos , Síndromes Paraneoplásicos del Sistema Nervioso/inmunologíaRESUMEN
Brainstem lesions are rarely associated with neurogenic pulmonary oedema (NPO) in multiple sclerosis and other disorders. The exact mechanism for this is unknown. We describe a case of a 15-year-old boy who presented with transient cardiomyopathy and severe acute pulmonary oedema. Several days after his initial presentation he developed an ataxic syndrome with limb, truncal and gait ataxia and nystagmus on primary gaze. Investigations confirmed acute disseminated encephalomyelitis (ADEM). For the first time, we describe a case of transient cardiomyopathy and NPO as the initial manifestation of ADEM.